PO26 | OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN UNUSUAL-SITE THROMBOSIS: IMPACT OF ACTIVE CANCER
S. Guglielmo1, M. Lovisotto1, L. Scarano1, E. De Bon2, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Introduction. Splanchnic vein thrombosis (SVT) and cerebral venous thrombosis (CVT) represent an unusual site of thrombosis. Cancer is among the most frequent predisposing conditions for SVT and CVT and is associated with an increased risk of bleeding and poor clinical outcomes. However, evidence supporting the use of direct oral anticoagulants (DOACs) in these settings remains limited, particularly in patients with active malignancy.
Aim. To evaluate the effectiveness and safety of DOAC therapy in patients with SVT or CVT and to compare outcomes between patients with and without active cancer.
Materials and Methods. This was a single-center longitudinal observational study with retrospective inclusion and prospective follow-up. Adult patients with imaging-confirmed SVT or CVT treated with a DOAC between January 2018 and October 2025 were included. The primary outcomes were radiological recanalization (absent, partial, or complete) and thrombotic recurrences. Secondary outcomes included ISTH major bleeding, clinically relevant non-major bleeding (CRNMB), and all-cause mortality. Follow-up imaging was scheduled at 6, 12, and 18 months.
Results. Of 52 screened patients, 43 were included (median age 58 years; 46.5% male); 26 had SVT and 17 CVT, with a median follow-up of 17 months. Active cancer was present in 16 patients. Most patients received initial parenteral anticoagulation (95.3%) before switching to a DOAC after a median of 14 days. DOACs used were dabigatran (41.5%), apixaban (36.5%), rivaroxaban (17.1%), and edoxaban (4.9%). Recanalization was assessable in 41 patients (14 with active cancer) and was complete in 18 (43.9%), partial in 12 (29.3%), and absent in 11 (26.8%). Active cancer was associated with a significantly lower likelihood of any recanalization (OR 0.094, 95% CI 0.019–0.464; p=0.003) and with a longer time to recanalization (log-rank p=0.007). Two thrombotic recurrences occurred (4.7%). Clinically relevant bleeding was observed in 7 patients (16.3%), including 3 major bleeding (7.0%) and 6 CRNMB events (14.0%). Seven deaths (16.3%) occurred, all among patients with active cancer and SVT.
Conclusions. In this real-world cohort of patients with SVT or CVT treated with DOACs, thrombotic recurrence and bleeding rates were acceptable. Active cancer identified a particularly high-risk subgroup characterized by reduced recanalization and all observed deaths, supporting cancer-specific studies and tailored management in unusual-site thrombosis.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Società Italiana di Emostasi e Trombosi, OC03 | THROMBOEMBOLIC PREVALENCE IN MULTIPLE MYELOMA BEFORE AND AFTER THE INTRODUCTION OF DIRECT ORAL ANTICOAGULANTS: A LONGITUDINAL COHORT STUDY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO67 | TARGETED THERAPIES FOR CANCER AND THE RISK OF ARTERIAL AND VENOUS THROMBOEMBOLISM , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO51 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF FACTOR XI-TARGETING MONOCLONAL ANTIBODIES SUPPORTS DURABLE ANTICOAGULANT COVERAGE AND TRANSLATIONAL DOSE AND REGIMEN SELECTION , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO09 | CANCER MORTALITY AFTER INCIDENT VENOUS THROMBOEMBOLISM , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO19 | THE INTER-RELATIONSHIP BETWEEN NETOSIS, THE ADAMTS-13/VWF AXIS, AND HEMOSTATIC ACTIVATION IN PATIENTS WITH GYNECOLOGICAL MALIGNANCIES: PROGNOSTIC SIGNIFICANCE AND IMPACT OF CHEMOTHERAPY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO55 | HISTORY OF CANCER IN PATIENTS WITH SEVERE HEREDITARY THROMBOPHILIA VERSUS NO THROMBOPHILIA: A SINGLE-CENTER COHORT OF PATIENTS WITH VENOUS THROMBOSIS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO57 | A NOVEL RISK ASSESSMENT MODEL FOR CANCER DETECTION WITHIN ONE YEAR AFTER INCIDENT VENOUS THROMBOEMBOLISM , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO03 | HEPATIC FIBROSIS–DRIVEN TISSUE FACTOR EXPRESSION BY MALIGNANT CHOLANGIOCYTES IS ASSOCIATED WITH CANCER-ASSOCIATED THROMBOSIS AND POOR SURVIVAL IN INTRAHEPATIC CHOLANGIOCARCINOMA , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO31 | MIGRATORY SUPERFICIAL THROMBOPHLEBITIS REFRACTORY TO APIXABAN IN A PATIENT WITH LUNG ADENOCARCINOMA , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
